Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
HYALGAN |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hyaluronan. |
| Generic Name |
|
Sodium hyaluronate 20mg/2mL; soln for intra-articular inj. |
| Indications |
|
Osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and analgesics (eg, acetaminophen). |
| Children |
|
Not recommended. |
| Adults |
|
Prior to treatment: remove joint effusion (use separate syringe), if present; and give local anesthetic (eg, lidocaine) by SC inj. Inject 2mL intra-articularly in each affected knee weekly for 5 weeks. Use separate syringes for each knee. |
| Contraindications |
|
Infection or skin disease at inj site. |
| Precautions |
|
Treatment cycles <3 injections: not recommended. Avian protein, feather, egg allergy. Avoid strenuous activity within 48hrs after injection. Pregnancy. Nursing mothers. |
| Interactions |
|
Avoid disinfectants with quaternary ammonium salts. Concomitant other intra-articular injectables: not recommended. |
| Adverse Reactions |
|
Inj site pain, local reactions, transient knee inflammation. |
| How Supplied |
Single-use vials—1
Single-use prefilled syringes—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
